Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Skak, K.
Right arrow Articles by Markholst, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skak, K.
Right arrow Articles by Markholst, H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 53:1089-1095, 2004
© 2004 by the American Diabetes Association, Inc.

Improved ß-Cell Survival and Reduced Insulitis in a Type 1 Diabetic Rat Model After Treatment With a ß-Cell–Selective KATP Channel Opener

Kresten Skak1, Carsten F. Gotfredsen1, Dorthe Lundsgaard2, John Bondo Hansen3, Jeppe Sturis1, and Helle Markholst2

1 Department of Pharmacology, Novo Nordisk A/S, Måløv, Denmark
2 Hagedorn Research Institute, Gentofte, Denmark
3 Department of Medicinal Chemistry, Novo Nordisk A/S, Måløv, Denmark

Treatment with ATP-sensitive K+ channel openers (KCOs) leads to inhibition of insulin secretion and metabolic "rest" in ß-cells. It is hypothesized that in type 1 diabetes this may reduce ß-cell death resulting from metabolic stress as well as reduce the immunogenicity of the ß-cells during autoimmune ß-cell destruction. We have investigated whether the ß-cell-selective KCO compound, NN414, can be used to improve ß-cell survival in DR-BB rats rendered diabetic by modulation of their immune system. The rats were treated three times daily on days 1–19 with NN414, diazoxide, or vehicle. On day 21, an intravenous glucose tolerance test was conducted to assess ß-cell function. Postmortem histological analysis of rats’ pancreata assessed the degree of insulitis and ß-cell volume. Among NN414-treated rats, 46% (16 of 35) were found to have a ß-cell mass similar to that of nondiabetic controls and significant glucose-stimulated C-peptide values, whereas only 11% (4 of 36) of vehicle-treated rats possessed a normal ß-cell mass and function (P < 0.002, by {chi}2 test). Furthermore, responsive NN414-treated rats were almost free of insulitis. Thus, this study demonstrated that treatment with KCO compounds can indeed lead to preservation of ß-cell function and reduction of insulitis in a rat diabetes model.

Address correspondence and reprint requests to Helle Markholst, MD, Hagedorn Research Institute, Niels Steensens Vej 6, 2820 Gentofte, Denmark. E-mail: hmar{at}novonordisk.com


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
B. Ng, Y. Kang, C. L. Elias, Y. He, H. Xie, J. B. Hansen, P. Wahl, and H. Y. Gaisano
The Actions of a Novel Potent Islet {beta}-Cell Specific ATP-Sensitive K+ Channel Opener Can Be Modulated by Syntaxin-1A Acting on Sulfonylurea Receptor 1
Diabetes, August 1, 2007; 56(8): 2124 - 2134.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
W. El-Kholy, P. E. MacDonald, J. M. Fox, A. Bhattacharjee, T. Xue, X. Gao, Y. Zhang, J. Stieber, R. A. Li, R. G. Tsushima, et al.
Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels in Pancreatic {beta}-Cells
Mol. Endocrinol., March 1, 2007; 21(3): 753 - 764.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Q. Huang, S. Bu, Y. Yu, Z. Guo, G. Ghatnekar, M. Bu, L. Yang, B. Lu, Z. Feng, S. Liu, et al.
Diazoxide Prevents Diabetes through Inhibiting Pancreatic {beta}-Cells from Apoptosis via Bcl-2/Bax Rate and p38-{beta} Mitogen-Activated Protein Kinase
Endocrinology, January 1, 2007; 148(1): 81 - 91.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Hambrock, C. B. de Oliveira Franz, S. Hiller, and H. Osswald
Glibenclamide-Induced Apoptosis Is Specifically Enhanced by Expression of the Sulfonylurea Receptor Isoform SUR1 but Not by Expression of SUR2B or the Mutant SUR1(M1289T)
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1031 - 1037.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. E. Rabaglia, M. P. Gray-Keller, B. L. Frey, M. R. Shortreed, L. M. Smith, and A. D. Attie
{alpha}-Ketoisocaproate-induced hypersecretion of insulin by islets from diabetes-susceptible mice
Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E218 - E224.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. Maedler, J. Storling, J. Sturis, R. A. Zuellig, G. A. Spinas, P. O.G. Arkhammar, T. Mandrup-Poulsen, and M. Y. Donath
Glucose- and Interleukin-1{beta}-Induced {beta}-Cell Apoptosis Requires Ca2+ Influx and Extracellular Signal-Regulated Kinase (ERK) 1/2 Activation and Is Prevented by a Sulfonylurea Receptor 1/Inwardly Rectifying K+ Channel 6.2 (SUR/Kir6.2) Selective Potassium Channel Opener in Human Islets
Diabetes, July 1, 2004; 53(7): 1706 - 1713.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.